*Division of Pathology, The Cancer Institute

†Department of Pathology, The Cancer Institute Hospital

§Department of Genitourinary Oncology, The Cancer Institute Hospital

∥Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research

‡Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan

K.K., J.S., and K.I.: conceived and designed the study. K.K., Y.S., G.A., E.S., J.Y., K.T., and K.I.: contributed to the acquisition of clinical and tumor tissue data. K.K. and Y.S.: performed data analyses. K.K., Y.S., and K.I.: interpretation of the findings. K.K. and K.I.: drafted the manuscript.

This study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Japanese Foundation for Cancer Research (protocol code: 2018-1177; date of approval: December 21, 2018).

Conflicts of Interest and Source of Funding: K.I. was financially supported by JSPS KAKENHI (Grant numbers JP22H02930 and JP23K18246), the Takeda Science Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Ichiro Kanehara Foundation, Suzuki Foundation for Urological Medicine, Foundation for Promotion of Cancer Research in Japan, and the Yakult Bio-Science Foundation. For the remaining authors, none were declared.

Correspondence: Kentaro Inamura, MD, PhD, Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan (e-mail: [email protected])

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.ajsp.com.